Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.

Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Muehlbauer MJ, Newgard CB, Borlaug BA, Kitzman DW, Shah SJ, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Lanfear DE, Javaheri A, Umpierrez G, Mentz RJ, Sharma K, Kosiborod MN, Shah SH

Open source

DOI: 10.1161/circheartfailure.124.011980
Published: 2024 Nov
Container: Circulation. Heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1161/circheartfailure.124.011980,
  title = {Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.},
  author = {Selvaraj S and Patel S and Sauer AJ and McGarrah RW and Jones P and Kwee LC and Windsor SL and Ilkayeva O and Muehlbauer MJ and Newgard CB and Borlaug BA and Kitzman DW and Shah SJ and Margulies KB and Husain M and Inzucchi SE and McGuire DK and Lanfear DE and Javaheri A and Umpierrez G and Mentz RJ and Sharma K and Kosiborod MN and Shah SH},
  year = {2024},
  journal = {Circulation. Heart failure},
  doi = {10.1161/circheartfailure.124.011980},
  url = {https://doi.org/10.1161/circheartfailure.124.011980}
}

RIS

TY  - JOUR
TI  - Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.
AU  - Selvaraj S
AU  - Patel S
AU  - Sauer AJ
AU  - McGarrah RW
AU  - Jones P
AU  - Kwee LC
AU  - Windsor SL
AU  - Ilkayeva O
AU  - Muehlbauer MJ
AU  - Newgard CB
AU  - Borlaug BA
AU  - Kitzman DW
AU  - Shah SJ
AU  - Margulies KB
AU  - Husain M
AU  - Inzucchi SE
AU  - McGuire DK
AU  - Lanfear DE
AU  - Javaheri A
AU  - Umpierrez G
AU  - Mentz RJ
AU  - Sharma K
AU  - Kosiborod MN
AU  - Shah SH
PY  - 2024
JO  - Circulation. Heart failure
DO  - 10.1161/circheartfailure.124.011980
UR  - https://doi.org/10.1161/circheartfailure.124.011980
ER  -

APA

S, S., S, P., AJ, S., RW, M., P, J., LC, K., SL, W., O, I., MJ, M., CB, N., BA, B., DW, K., SJ, S., KB, M., M, H., SE, I., DK, M., DE, L., A, J., G, U., RJ, M., K, S., MN, K., & SH, S. (2024). Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.. Circulation. Heart failure. https://doi.org/10.1161/circheartfailure.124.011980

Source records

pubmed · retrieved 2026-09-26T17:07:55.857Z